128 related articles for article (PubMed ID: 37332171)
1. Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study.
Hauck TS; Ladha KS; Le Foll B; Wijeysundera DN; Kurdyak P
Addiction; 2023 Oct; 118(10):1953-1964. PubMed ID: 37332171
[TBL] [Abstract][Full Text] [Related]
2. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
3. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
[TBL] [Abstract][Full Text] [Related]
4. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
5. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
[TBL] [Abstract][Full Text] [Related]
6. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
7. Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy.
Mehta D; Thomas V; Johnson J; Scott B; Cortina S; Berger L
Pain Physician; 2020 Mar; 23(2):E163-E174. PubMed ID: 32214293
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
9. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
10. Continuation of Buprenorphine During Hospitalization and Subsequent Retention in Therapy: an Observational Study in Veterans Administration Hospitals.
Mosher HJ; Hadlandsmyth K; Alexander B; Lund BC
J Gen Intern Med; 2024 Feb; 39(2):207-213. PubMed ID: 37752303
[TBL] [Abstract][Full Text] [Related]
11. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
[TBL] [Abstract][Full Text] [Related]
13. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Williams AR; Samples H; Crystal S; Olfson M
Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation.
Quaye A; Potter K; Roth S; Acampora G; Mao J; Zhang Y
Pain Med; 2020 Sep; 21(9):1955-1960. PubMed ID: 32167541
[TBL] [Abstract][Full Text] [Related]
15. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
16. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
17. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
[TBL] [Abstract][Full Text] [Related]
19. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
[TBL] [Abstract][Full Text] [Related]
20. Perioperative Management of Buprenorphine/Naloxone in a Large, National Health Care System: a Retrospective Cohort Study.
Wyse JJ; Herreid-O'Neill A; Dougherty J; Shull S; Mackey K; Priest KC; Englander H; Thoma J; Lovejoy TI
J Gen Intern Med; 2022 Sep; 37(12):2998-3004. PubMed ID: 34545469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
